[HTML][HTML] Camrelizumab plus apatinib in extensive-stage SCLC (PASSION): a multicenter, two-stage, phase 2 trial
Y Fan, J Zhao, Q Wang, D Huang, X Li, J Chen… - Journal of Thoracic …, 2021 - Elsevier
Introduction Treatment options in the second-line extensive-stage SCLC (ED-SCLC) setting
are limited. The PASSION study (ClinicalTrials. gov identifier: NCT03417895) was a phase 2 …
are limited. The PASSION study (ClinicalTrials. gov identifier: NCT03417895) was a phase 2 …
Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial
Y Fan, J Zhao, Q Wang, D Huang… - Journal of thoracic …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction Treatment options in the second-line extensive-stage SCLC (ED-SCLC) setting
are limited. The PASSION study (ClinicalTrials. gov identifier: NCT03417895) was a phase 2 …
are limited. The PASSION study (ClinicalTrials. gov identifier: NCT03417895) was a phase 2 …
Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial.
Y Fan, J Zhao, Q Wang, D Huang, X Li… - Journal of Thoracic …, 2020 - europepmc.org
Methods In stage I of the study, patients were randomized (1: 1: 1) to receive camrelizumab
200 mg every 2 weeks plus apatinib 375 mg once daily (QD), 5 days on and 2 days off, or 7 …
200 mg every 2 weeks plus apatinib 375 mg once daily (QD), 5 days on and 2 days off, or 7 …
[HTML][HTML] Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial
Y Fan, J Zhao, Q Wang, D Huang, X Li, J Chen… - Journal of Thoracic …, 2021 - jto.org
Introduction Treatment options in the second-line extensive-stage SCLC (ED-SCLC) setting
are limited. The PASSION study (ClinicalTrials. gov identifier: NCT03417895) was a phase 2 …
are limited. The PASSION study (ClinicalTrials. gov identifier: NCT03417895) was a phase 2 …